MRD-negativity rates after induction and after consolidation with quadruplets in TE NDMM patients
| . | Type of quadruplet . | Number of patients/ specific population . | Induction details . | Postinduction MRD-negativity rate . | Number of ASCTs . | Consolidation details . | Postconsolidation/premaintenance MRD-negativity rate . | Outcomes . |
|---|---|---|---|---|---|---|---|---|
| CASSIOPEIA37 | DaraVTD | 543 | 4 (4-week) cycles | 35% (10–5) | 1 | 2 (4-week) cycles | 64% (10–5) | mPFS 83.7 m |
| GRIFFIN38 | DaraVRD | 104 | 4 (3-week) cycles | 22% (10–5) 1% (10–6) | 1 | 2 (3-week) cycles | 50% (10–5) 11% (10–6) | 4-y PFS 70% |
| PERSEUS39 | DaraVRD | 355 | 4 (4-week) cycles | NA | 1 | 2 (4-week) cycles | 57% (10–5) 34% (10–6) | 4-y PFS 84% |
| GMMG-HD740 | IsaVRD | 331 | 3 (6-week) cycles | 50% (10–5) | 1 | No consolidation | 72% (10–5) | NA |
| IFM2018-0141 | DaraIxaRD | 45 (SR) | 6 (3-week) cycles | 28% (10–5) 6% (10–6) | 1 | 4 (4-week) cycles | 51% (10–5) 40% (10–6) | 2-y PFS 93% |
| IFM2018-0436 | DaraKRD | 50 (HR) | 6 (4-week) cycles | 53% (10–5)a 43% (10–6)a | 2 | 4 (4-week) cycles | 97% (10–5)a 94% (10–6)a | 2.5-y PFS 80% |
| GMMG-CONCEPT35 | IsaKRD | 99 (HR) | 6 (4-week) cycles | NA | 2 | 4 (4-week) cycles | 68% (10–5) | 3-y PFS 69% |
| EMN24 IsKia42 | IsaKRD | 151 | 4 (4-week) cycles | 45% (10–5) 27% (10–6) | 1 | 4 (4-week) cycles | 77% (10–5) 67% (10–6) | NA |
| MASTER44 | DaraKRD | 123 | 4 (4-week) cycles | 37% (10–5) 23% (10–6) | 1 | MRD adapted | NA | NA |
| IFM2020-0222 | IsaKRD | 791 | 6 (4-week) cycles | 63% (10–5) 47% (10–6) | 0, 1, or 2 | MRD adapted | NA | NA |
| . | Type of quadruplet . | Number of patients/ specific population . | Induction details . | Postinduction MRD-negativity rate . | Number of ASCTs . | Consolidation details . | Postconsolidation/premaintenance MRD-negativity rate . | Outcomes . |
|---|---|---|---|---|---|---|---|---|
| CASSIOPEIA37 | DaraVTD | 543 | 4 (4-week) cycles | 35% (10–5) | 1 | 2 (4-week) cycles | 64% (10–5) | mPFS 83.7 m |
| GRIFFIN38 | DaraVRD | 104 | 4 (3-week) cycles | 22% (10–5) 1% (10–6) | 1 | 2 (3-week) cycles | 50% (10–5) 11% (10–6) | 4-y PFS 70% |
| PERSEUS39 | DaraVRD | 355 | 4 (4-week) cycles | NA | 1 | 2 (4-week) cycles | 57% (10–5) 34% (10–6) | 4-y PFS 84% |
| GMMG-HD740 | IsaVRD | 331 | 3 (6-week) cycles | 50% (10–5) | 1 | No consolidation | 72% (10–5) | NA |
| IFM2018-0141 | DaraIxaRD | 45 (SR) | 6 (3-week) cycles | 28% (10–5) 6% (10–6) | 1 | 4 (4-week) cycles | 51% (10–5) 40% (10–6) | 2-y PFS 93% |
| IFM2018-0436 | DaraKRD | 50 (HR) | 6 (4-week) cycles | 53% (10–5)a 43% (10–6)a | 2 | 4 (4-week) cycles | 97% (10–5)a 94% (10–6)a | 2.5-y PFS 80% |
| GMMG-CONCEPT35 | IsaKRD | 99 (HR) | 6 (4-week) cycles | NA | 2 | 4 (4-week) cycles | 68% (10–5) | 3-y PFS 69% |
| EMN24 IsKia42 | IsaKRD | 151 | 4 (4-week) cycles | 45% (10–5) 27% (10–6) | 1 | 4 (4-week) cycles | 77% (10–5) 67% (10–6) | NA |
| MASTER44 | DaraKRD | 123 | 4 (4-week) cycles | 37% (10–5) 23% (10–6) | 1 | MRD adapted | NA | NA |
| IFM2020-0222 | IsaKRD | 791 | 6 (4-week) cycles | 63% (10–5) 47% (10–6) | 0, 1, or 2 | MRD adapted | NA | NA |
Exceptions to MRD reported in intention-to-treat population (per protocol).
HR, (cytogenetics) high-risk; NA, not available; SR, (cytogenetics) standard risk.